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Abstract
Introduction Epithelial tumors, including breast cancer, are
being identified and treated at earlier stages of tumor
development because of technological advances in screening
and detection methods. It is likely that early-stage epithelial
tumors, such as mammary ductal carcinoma in situ (DCIS), will
be amenable to new and more efficacious diagnostic tests and
forms of therapy. However, our limited understanding of the
underlying molecular mechanisms of early-stage epithelial tumor
growth has hampered the development of new forms treatment
and preventative therapy.
Methods The Raf–MEK1/2–ERK1/2 mitogen-activated protein
kinase module is activated by stimuli complicit in mammary
neoplastic progression. We have recently demonstrated that the
activation of ERK1/2 induces a non-invasive form of motility,
where cells can track along the basement membrane and
adjacent epithelial cells, but do not become invasive over time,
using real-time imaging of a mammary epithelial organotypic
culture model. Using this novel approach combined with
traditional biochemical techniques, we have analyzed at the
molecular level how ERK1/2 induces this new non-invasive form
of motility as well as proliferation and cell survival.
Results We find that the activation of Raf:ER in the
differentiated epithelium of fully formed acini promotes
proliferation and cell survival, which are characteristic features
of pre-invasive DCIS lesions. The activation of ERK1/2
correlated with induction of c-Fos, a transcriptional regulator of
proliferation and reduced expression of the pro-apoptotic BH3-
only protein BIM. Both ERK1/2 and PI-3 kinase-dependent
effector pathways were required for activated Raf:ER to reduce
expression of p27 and promote proliferation. In addition, PI-3K
activity was necessary for the induction of non-invasive motility
induced by ERK1/2.
Conclusions ERK1/2 activation is sufficient to induce cell
behaviors in organotypic culture that could promote recurrent
and invasive growth in DCIS patients. Interestingly, PI-3K activity
is necessary for two of these behaviors, proliferation and cell
motility. Collectively, our results suggest that the relationship
between the activity state of the ERK1/2 and PI-3K signaling
pathways and recurrent growth in DCIS patients should be
investigated.
Introduction
Epithelial cancers, such as breast cancer, are being more fre-
quently identified at the early pre-invasive stage of tumor
development [1]. These pre-invasive mammary lesions origi-
nate from the luminal epithelial cells that line the ducts and lob-
ules of the mammary glandular epithelium and have a
disrupted epithelial architecture characterized by hyperprolif-
erative cells occupying the normally hollow luminal spaces of
the ducts and lobules [2,3]. The amplification and overexpres-
sion of the receptor tyrosine kinase ErbB2 is observed in
approximately 50% of pre-invasive lesions; however, in most
cases, the genetic and epigenetic abnormalities that promote
pre-invasive tumor growth are poorly understood [4].
Since such a wide range of molecular perturbations can
induce and enhance tumor growth, there are probably shared
molecular signaling modules that integrate biochemical sig-
nals from the suite of genetic contexts found in epithelial
tumors [5]. To explain how normal cells become tumorigenic,
a molecular framework that underpins the pre-invasive stage of
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tumor growth must be established. Such a molecular frame-
work can assist in the identification of patients amenable to
targeted therapeutics, in the development of novel therapeu-
tics to treat pre-invasive cancer, and, in the future, in the intro-
duction of preventative treatment [6]. Attempts to identify the
core signaling modules that promote these pre-invasive
growth characteristics through the analysis of genetic abnor-
malities and gene expression patterns of pre-invasive tumor
lesions have to date been unsuccessful [7-9].
The Raf–MEK1/2–ERK1/2 mitogen-activated protein kinase
signal transduction module transmits extracellular and onco-
genic stimuli, resulting in cellular responses [10]. In this mod-
ule, Raf isoforms phosphorylate their primary substrates, the
dual-specificity kinases MEK1/2. Once activated, MEK1/2
phosphorylate ERK1/2 on tyrosine and threonine residues,
substantially increasing ERK1/2 catalytic activity [11]. The
Raf–MEK1/2–ERK1/2 module is activated by growth factors
and proteins overexpressed in human breast cancer epithe-
lium, by cytokines and hormones produced by fibroblasts and
macrophages in the mammary stromal compartment, and by
increased tissue stiffness observed during tumor progression
[10,12]. In addition, the sequencing of breast cancer patient
genomes suggests that infrequent mutations may drive tumor
progression through known signaling pathways, such as the
Raf–MEK1/2–ERK1/2 cascade [5]. Considering the array of
stimuli known to activate the Raf–MEK1/2–ERK1/2 module, it
may be complicit in tumorigenesis in a variety of contexts.
Consistent with a role for the Raf–MEK1/2–ERK1/2 module in
mammary carcinogenesis, ERK1/2 are activated in primary
breast cancer tissue and in associated lymph node metas-
tases [13,14]. The activation of ERK1/2 is not associated with
a specific genetic signature, however, as ERK1/2 is active in
ER-positive breast cancer, HER2-positive breast cancer and
in triple-negative breast cancer [15]. ERK1/2 phosphorylate
transcription factors, kinases, proteases and non-enzymatic
regulatory proteins, thus potentially integrating the Raf–
MEK1/2–ERK1/2 module into a range of cellular activities
associated with tumorigenesis [16]. Accumulating evidence,
however, has shown that results obtained in one cell type
should not be generally applied across all classes of cancer
without experimental validation [6]. For example, the K-Ras2
oncogene has distinct effects on tumor progression depend-
ing on both the cell type of origin and the genetic context in
which it is mutated [6]. In addition, extrapolating the role of
protein kinases in promoting breast cancer progression based
on either their known substrate profile or biological behaviors
induced in two-dimensional culture models has proven to be
unreliable [17,18]. For example, the chemically induced
homodimerization of the epidermal growth factor receptor
(EGFR) is sufficient to induce focus formation in Rat 1 cells
and the proliferation of MCF-10A mammary epithelial cells in
monolayer cultures [17,19]. EGFR homodimerization of
EGFR, however, is not sufficient to induce the proliferation of
differentiated MCF-10A cells grown in organotypic culture
[17]. Considering the uncertainty in predicting the response of
cells to the activation of a signaling pathway, determining the
response of differentiated mammary epithelial cells to Raf–
MEK–ERK activation can better define the early events of
mammary tumorigenesis.
Three-dimensional organotypic culture models have been
indispensable tools in deciphering the molecular and cell bio-
logical mechanisms underlying the disruption of differentiated
epithelial architecture that is characteristic of pre-invasive
mammary epithelial lesions. In organotypic culture models,
individual mammary epithelial cells plated on reconstituted
basement membrane proliferate to form a hollow sphere of
polarized, growth-arrested cells (termed acini), thus recapitu-
lating the salient features of the mammary gland [20,21].
Since the mammary epithelial cells differentiate and form a hol-
low monolayer of cells, organotypic cultures provide a more
accurate reconstitution of the biochemical and cell biological
growth restraints found in mammary glandular epithelium than
is achieved using traditional two-dimensional cell culture mod-
els [22]. Once cells become proliferative, they are confronted
with similar local environmental selection pressures to those
found during tumorigenesis. Namely, cells are required to
become resistant to cell death triggered by the induction of
either apoptosis or autophagy when cells enter the luminal
space [23,24]. Organotypic culture models therefore provide
both the biochemical signaling barriers that must be overcome
for initial proliferation to occur, and the microenvironmental
context in which pre-invasive tumor cells must survive and
propagate.
We have previously developed a method for imaging cells in
Raf:ER-induced acini at single-cell resolution through imaging
a histone–green fluorescence protein (GFP) correct fusion
protein, H2B-GFP [25]. Using this unbiased discovery
approach we have found that Raf:ER activation induces a dis-
ruption of epithelial architecture through promoting a non-inva-
sive form of motility, cell proliferation and the survival of cells in
the lumen. These findings suggest that ERK1/2 activation can
promote the early events of tumorigenesis and that the induc-
tion of motility can, in principle, occur before tumor cell inva-
sion. To determine how ERK1/2 signaling promotes the early
events of tumorigenesis we have examined the intracellular
signaling pathways that promote proliferation, cell survival and
motility in response to ERK1/2 activation in mammary epithe-
lial acini.
Materials and methods
Cell culture and reagents
MCF-10A human mammary epithelial cells were obtained from
the American Type Tissue Culture Collection. Cells were cul-
tured in DMEM/F12 (Gibco, Invitrogen, Carlsbad, CA, USA)
supplemented with 5% horse serum (Gibco, Carlsbad, CA,
USA), 10 μg/ml insulin (Research Diagnostics, Inc., Concord,Available online http://breast-cancer-research.com/content/11/3/R29
Page 3 of 14
(page number not for citation purposes)
MA, USA), 20 ng/ml epidermal growth factor (Research Diag-
nostics, Inc.), 500 ng/ml hydrocortisone (Sigma, St Louis, MO,
USA), 100 ng/ml cholera toxin (Calbiochem, San Diego, CA,
USA) and cyprofloxacin (Cellgro, Carlsbad, CA, USA). The
growth-factor-reduced Matrigel (BD Biosciences, Franklin
Lakes, NJ, USA) used in these experiments had protein con-
centrations between 10 and 12 mg/ml. 4-Hydroxytamoxifen
(4-HT), LY294002, U0126 and AG1478 were from Calbio-
chem. Antibodies recognizing Ki-67 (Zymed, San Francisco,
CA, USA), c-Fos, estrogen receptor alpha and cyclin B1
(Santa Cruz, Santa Cruz, CA, USA), phosphorylated AKT
(S473), cleaved caspase 3, Bim and Bim (IF specific) (Cell
Signaling, Beverly, MA, USA), p27 (BD Transduction Labs)
and phosphorylated ERK2 (T183, Y185) (Sigma) were used.
Secondary antibodies for immunofluorescence staining were
labeled with Alexa fluor 488, 568 and 647 (Molecular Probes,
Invitrogen, Carlsbad, CA, USA).
Three-dimensional morphogenesis assay and cell lines
MCF-10A cells plated in eight-well chamberslides (Falcon,
San Jose, CA, USA) were cultured as described previously
[25]. The vector pBABE-Raf:ER was a gift from Michael White
and Ron Bumeister (University of Texas Southwestern Medical
Center, Dallas, USA), pBABE-GFP-Raf:ER was a gift from
Martin McMahon (University of California San Francisco, USA)
and pCLNRX-H2B:GFP was a gift from Ee Tsin Wong and
Geoff Wahl (Salk Institute, La Jolla, CA, USA). VSVG-pseudo-
typed virus was generated by transfecting HEK293 cells sta-
bly expressing Gag and Pol with VSVG and pBABE-Raf:ER or
pCLNRX-H2B:GFP. Cells were cultured in 500 ng/ml puro-
mycin or 400 μg/ml G418 to create stable pools of pBABE-
Raf:ER MCF-10A cells or pCLNRX-H2B:GFP MCF-10A cells.
The GFP-Raf:ER MCF-10A cells did not undergo drug selec-
tion.
Immunoblot analysis and immunofluorescence staining
The acini were lysed in RIPA buffer supplemented with pro-
tease and phosphatase inhibitors as described elsewhere
[25], and protein levels were normalized using Cyto-tox One
(Promega, Madison, WI, USA) according to the manufac-
turer's instructions. Immunoblots were visualized using an
Odyssey infrared scanner (LI-COR, Lincoln, NE, USA). Cul-
tures were fixed in 2% formalin (Sigma Aldrich, St. Louis, MO,
USA) for 20 minutes and were permeabilized with 0.5% Triton
X-100 in PBS for 10 minutes at room temperature. Immunos-
taining was performed as described previously [25].
Images were acquired on a Leica SP2 AOBS confocal micro-
scope (Bannockburn, IL, USA) using Leica software in TIFF
format. Images were arranged using Adobe Photoshop 7.0
and Keynote, and are representative of at least three inde-
pendent experiments. For quantification of immunofluores-
cence images, either three or more Ki-67-positive cells per
acinus or two or more phospho-AKT-positive cells per acinus
were used as thresholds, as has been previously reported
[17,24,26]. These thresholds reproducibly distinguish
between control acini with normal architectures and Raf:ER-
induced acini with disrupted architectures from experiment to
experiment.
Real-time imaging
Organotypic cultures were grown in eight-well chambered
coverglass slides (Thermo Fisher Scientific, Pittsburgh, PA,
USA) as described above and previously [25]. Cultures were
imaged with a spinning disk confocal scanhead (QLC100;
Yokagowa, Newnan, Georgia, USA) enclosed in a 37°C
chamber supplemented with humidified carbon dioxide
(Solent, Segensworth, UK) and a CCD camera (C9100-02
EM-charged coupled device; Hamamatsu, Hammamatsu,
Japan). Images were acquired with a 40×/0.60 objective
(HCX Plan Fluor; Leica) using SimplePCI software (Compix,
Hammamatsu, Japan) and were analyzed with Imaris software
(Bitplane, Zurich, Switzerland). At least six different x,y coordi-
nates with three or more z-slices over 20 μm for each condi-
tion were imaged in parallel for three independent
experiments.
Results
Activation of the Raf–MEK1/2–ERK1/2 mitogen-
activated protein kinase module promotes increased 
proliferation and resistance to apoptosis
To elucidate how the Raf–MEK1/2–ERK1/2 module could
promote pre-invasive tumor growth, we examined the
response of a model human mammary epithelial cell line, MCF-
10A, to activation of Raf in an organotypic culture model [25].
To activate Raf, a 4-HT-inducible, constitutively active variant
of Raf-1, termed Raf:ER, was stably expressed in the MCF-
10A cells [25,27]. The Raf:ER fusion protein consists of the
kinase domain of Raf fused to a modified ligand-binding
domain of the estrogen receptor at the C-terminus [28]. Treat-
ment of cells with 4-HT activates Raf:ER by increasing Raf:ER
protein stability and perhaps inducing conformational changes
[29].
Using real-time imaging we have previously demonstrated that
the activation of Raf:ER promotes the disruption of epithelial
architecture of MCF-10A acini through the induction of a new
non-invasive form of mammary epithelial cell motility [25]. In
addition to cell motility, our real-time imaging analysis of
Raf:ER-induced acini showed some cells transitioning through
mitosis and that cells occupying the luminal space did not
undergo apoptosis [25]. If Raf:ER induction was indeed induc-
ing significant proliferation and cell survival, the size of acini
should increase over time. To test this possibility we first grew
Raf:ER-MCF-10A cells for 12 days in three-dimensional orga-
notypic culture to generate acini with differentiated epithelium
and a hollow lumen that are identical to wild-type MCF-10A
acini (data not shown). These fully formed acini were then
treated with diluent or 100 nM 4-HT for 5 days. To simplify
interpretation, exogenous epidermal growth factor (EGF),Breast Cancer Research    Vol 11 No 3    Pearson and Hunter 
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which is normally present at 1 ng/ml in organotypic culture
growth medium, was omitted from the medium at the time of
treatment with 4-HT in all experiments.
Acini treated with 4-HT at day 12 lost their spherical shape
and were larger then control acini (Figure 1a), as judged by dif-
ferential interference contrast microscopy. Raf:ER expression
was typically increased in at least 90% of cells within an indi-
vidual acinar structure 48 hours after administration of 4-HT
(data not shown), and the induction of Raf:ER promoted a
large increase in the level of activated ERK1/2 (Figure 1b).
Examination of the arrangement of cells, as judged by the posi-
tion of nuclei and appearance under differential interference
contrast microscopy, revealed a loss of spherical architecture
and of cells occupying the lumens of acini (Figure 1a,c), con-
sistent with our previous findings [25].
To determine the frequency with which Raf:ER activation
increases cell proliferation, acini treated with 4-HT for 48
hours were fixed and immunostained with an antibody towards
Ki-67, a marker of proliferation. Only 17% of the control acini
contained three or more cells expressing Ki-67, whereas 65%
of the acini treated with 4-HT had three or more cells express-
ing Ki-67, indicating that the activation of ERK1/2 is sufficient
to stimulate an increased rate of proliferation in cultured acini
(Figure 1c,d).
A key step in the development of breast cancer is survival of
cells in the luminal space [3]. Previous studies have demon-
strated that normal cells in the lumen undergo caspase-
dependent apoptosis as indicated by positive staining for the
cleaved and activated forms of caspase 3 and caspase 9 [24].
We found that, unlike control acini, Raf:ER-expressing MCF-
10A acini had few if any cleaved caspase-3-containing cells in
their lumens, indicating that these cells were resistant to apop-
tosis (Figure 1c). Collectively, these results demonstrate that
the activation of Raf:ER in differentiated epithelium induces an
expansion of acinar size and filling of the luminal space through
the coordination activation of both proliferative and prosurvival
signaling pathways in organotypic culture.
Raf:ER does not require autocrine activation of EGFR to 
promote the disruption of epithelial architecture
The characterization of Raf–MEK1/2–ERK1/2 signaling in
two-dimensional culture systems has suggested a predomi-
nant role for the autocrine activation of EGFR in ERK1/2-
driven proliferation and cell survival [30,31]. Considering
ERK1/2 are active in epithelial cancers, including breast can-
cer, if ERK1/2 requires autocrine activation of EGFR, than the
therapeutic blockade of EGFR will block ERK1/2-driven tum-
origenic responses. Determining the contribution of EGFR to
ERK1/2-driven pre-invasive mammary epithelial cell growth is
therefore critical considering the current clinical trials investi-
gating therapeutic inhibitors of EGFR [32].
Figure 1
Activation of Raf:ER induces pre-invasive epithelial growth in cultured acini Activation of Raf:ER induces pre-invasive epithelial growth in cultured acini. (a) Raf:ER-MCF-10A cells plated for three-dimensional culture were 
grown for 10 days. At day 10, diluent or 100 nM 4-hydroxytamoxifen (4-HT) was added and cultures were grown for an additional 5 days. Differential 
interference contrast images are shown. Bars = 150 μM. (b) The lysates of day 10 acini treated for 48 hours with diluent or 100 nM 4-HT were 
immunoblotted with α-phospho-ERK1/2 (top) and α-ERK1/2 antibodies. (c) Raf:ER-MCF-10A cells were grown as described in (a). Confocal cross-
sections of acini immunostained with α-Ki-67 (green) and α-cleaved caspase 3 (red) and counterstained with Hoechst (blue) are shown. Bars = 50 
μm. (d) The percentage of acini containing three or more Ki-67 cells was quantified. Data are the mean ± standard error of the mean of 100 acini 
counted in three independent experiments.Available online http://breast-cancer-research.com/content/11/3/R29
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We tested whether autocrine EGFR activation was necessary
for proliferation in organotypic culture using the pharmacolog-
ical EGFR kinase inhibitor AG1478. We found that inhibiting
EGFR activity with 300 nM AG1478 had no effect on the
Raf:ER-induced disruption of epithelial architecture or stimula-
tion of proliferation as judged by Ki-67 staining (Figure 2a). It
has been suggested that cells in the lumens of acini undergo
anoikis due to their inability to interact with basement mem-
brane [24]. Resistance to anoikis in Raf:ER-MCF-10A cells
requires activation of EGFR, so we examined whether EGFR
activation is necessary for survival of cells in the lumens of
Raf:ER-induced acini [33]. Blockade of EGFR kinase activity
with AG1478 did not cause caspase-dependent apoptosis in
lumens of Raf:ER-induced acini as judged by immunostaining
for cleaved caspase 3 (Figure 2a).
We next determined whether ERK1/2 activation induces the
production of autocrine growth factors in organotypic culture.
Since the growth of MCF-10A cells in organotypic culture is
absolutely dependent on EGF [21], we reasoned that if
Raf:ER-induced acini are producing autocrine EGFR agonists,
then Raf:ER-induced acini could support the growth of wild-
type MCF-10A cells cultured in the absence of exogenous
EGF [18]. To distinguish wild-type MCF-10A cells from the
Raf:ER-MCF-10A cells, we generated a wild-type MCF-10A
cell line that stably expressed the H2B-GFP fusion protein.
Raf:ER cells were co-cultured with MCF-10A-H2B:GFP cells
at a 1:1 plating ratio. The cultures were grown with diluent or
100 nM 4-HT in the absence of EGF for 13 days. In the control
cultures treated with diluent, neither Raf:ER cells nor the MCF-
10A-H2B:GFP cells proliferated to form acini. On the other
hand, when Raf:ER was activated by 100 nM 4-HT, both the
Raf:ER cells and the MCF-10A-H2B:GFP cells grew to form
acini (Figure 2b). Over 85% of Raf:ER and MCF-10A/
H2B:GFP cells grew to acini of at least 30 μM in diameter.
The acini are not mixed groups of cells, because acini are
entirely formed from cells that express H2B:GFP or from cells
that do not (Figure 2b). The ability of acini expressing activated
Raf:ER to promote growth of co-cultured normal MCF-10A
acini in the absence of EGF indicates that activated Raf:ER
acini secrete autocrine growth factors that complement the
absence of EGF. We confirmed that the growth-promoting
autocrine growth factors were acting on EGFR by growing the
co-cultures in the presence of 300 nM AG1478 (Figure 2b).
Only one or two acini out of 100 MCF-10A/H2B:GFP cells
counted grew larger than five cells in three independent exper-
iments. Activation of ERK1/2 in differentiated mammary epi-
thelium does indeed therefore induce the production of
autocrine growth factors that act on EGFR. One candidate
factor is heparin-binding EGF [30].
Raf:ER activation promotes the induction of c-Fos and 
the decreased expression of Bim
We next explored the intracellular targets of ERK1/2 that pro-
mote proliferation and cell survival. Immediate early gene prod-
ucts, such as the transcription factor c-Fos, regulate cell
proliferation in a variety of cell types [34]. ERK1/2 can
enhance c-Fos expression through indirect regulation of c-fos
transcription and phosphorylation-dependent stabilization of
c-Fos protein [35]. Whether c-Fos expression is elevated in
response to ERK1/2 activation or any oncogenic stimuli in dif-
ferentiated epithelium in organotypic culture is not known. We
examined c-Fos expression in day 10 acini or later acini after
treatment with 100 nM 4-HT for 48 hours by immunostaining,
and found that c-Fos protein levels were increased in acini
treated with 100 nM 4-HT (Figure 3a). The elevated expres-
sion of c-Fos suggests that ERK1/2-stimulated proliferation
could in part be regulated by c-Fos. The single-cell-level anal-
ysis provided by our immunofluorescence analysis also dem-
onstrates that c-Fos expression does not directly correlate
with the degree of disruption of epithelial architecture (Figure
3a). This indicates that the variations in epithelial phenotype
that are observed are not simply due to differences in the level
of c-Fos expression, and demonstrates the complexity of intra-
Figure 2
Autocrine epidermal growth factor receptor activation unnecessary for  ERK1/2 stimulation of proliferation or apoptosis resistance Autocrine epidermal growth factor receptor activation unnecessary for 
ERK1/2 stimulation of proliferation or apoptosis resistance. (a) Acini 
were grown for 10 days and then treated with diluent, with 100 nM 4-
hydroxytamoxifen (4-HT) or with 100 nM 4-HT + 300 nM AG1478 (epi-
dermal growth factor receptor (EGFR) inhibitor) and were immunos-
tained with α-Ki-67 (green) and α-cleaved caspase 3 (red) antibodies 
and counterstained with Hoechst (blue). The acini shown are repre-
sentative of 100 acini observed in three independent experiments. No 
more then 10 acini in the 4-HT-treated acini or 4-HT + AG1478-treated 
acini had greater then 10% of cells in the lumen stain positive for 
cleaved caspase 3 in any of the experiments. Bar = 75 μm. DMSO, 
dimethylsulfoxide. (b) Raf:ER-expressing and H2B:GFP-expressing 
MCF-10A cells were plated at a 1:1 ratio and grown in three-dimen-
sional culture for 13 days with diluent, with 100 nM 4-HT in the 
absence of EGF, or with 100 nM 4-HT, no EGF and 300 nM AG1478 
(EGFR inhibitor). The nuclei of Raf:ER acini are seen with Hoechst 
(blue) and the nuclei of the H2B:GFP-MCF-10A cells are visualized 
with green fluorescence protein (GFP) (green) overlaying Hoechst 
(blue). Bar = 50 μm.Breast Cancer Research    Vol 11 No 3    Pearson and Hunter 
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cellular biochemical signaling involved in stimulating pre-inva-
sive growth in organotypic culture.
When cells occupy the lumens of MCF-10A acini, cell survival
cues provided by integrin contacts with the basement mem-
brane are lost. The intracellular signaling architecture of epi-
thelial cells must therefore be altered for cells to survive in the
luminal space. The expression level of the protein proapoptotic
BH3 domain-containing protein Bim is incrementally
increased in all of the MCF-10A cells as they differentiate and
form acini in organotypic culture [36]. This apoptotic trigger is
counterbalanced by unknown biochemical signals stimulated
by cell attachment to the surrounding basement membrane
[36]. Reduced expression of Bim is sufficient to delay apopto-
sis of cells in lumens of MCF-10A acini and the developing
mammary gland, which suggests that the differentiation-
dependent increase in Bim expression triggers apoptosis of
centrally located cells and formation of a lumen [36,37]. Stable
expression of a constitutively active form of MEK1 is sufficient
to reduce Bim expression in MCF-10A acini, and Raf:ER
induction can reduce Bim expression in MCF-10A cells in
monolayer culture and in detached cells [33,36]. The suffi-
ciency of acute ERK1/2 activation to reduce Bim expression in
differentiated mammary epithelium, however, has not been
tested. We examined Bim expression 48 hours after Raf:ER
activation by immunostaining and immunoblotting, and found
the Bim expression level was indeed decreased (Figure 3b,c).
This result suggests that Raf:ER activation promotes resist-
ance to apoptosis and the occupation of the lumen by mam-
mary epithelial cells in part through decreasing the expression
level of Bim.
Raf:ER activation of AKT promotes degradation of p27 
and cell cycle progression in mammary organotypic 
culture
Previous studies in two-dimensional culture models have
shown that Raf:ER indirectly stimulates the phosphorylation of
the AGC kinase AKT on serine 473 [30]. Overexpression of
AKT1 is sufficient to delay MCF-10A growth arrest in three-
dimensional culture and cooperates with overexpressed cyclin
D1 or the viral oncoprotein HPV E7 to promote proliferation
[18]. AKT also regulates proliferation in malignant T4-2 mam-
mary epithelial cells in three-dimensional culture [38].
Considering the potential role of AKT signaling in the disrup-
tion of epithelial architecture induce by Raf:ER, we examined
the activation state of AKT using an antibody that recognizes
AKT phosphorylated at serine 473 by immunostaining. We
Figure 3
Raf:ER activates multiple downstream effectors Raf:ER activates multiple downstream effectors. Raf:ER three-dimen-
sional cultures were grown for 10 days, treated with diluent or 100 nM 
4-hydroxytamoxifen (4-HT) and grown for an additional 48 hours. (a) 
Acini were immunostained with α-c-Fos (red) and counterstained with 
Hoechst (blue). Bar = 150 μm. (b) Acini were immunostained with α-
Bim antibody (red) and counterstained with Hoechst (blue). Bar = 30 
μm. (c) The lysates of acini were immunoblotted with α-Bim antibody 
(upper panel) or α-α-tubulin (bottom panel) antibodies. The Bim signal 
intensity from the 4-HT-treated acini normalized to the tubulin signal 
intensity and divided by the normalized Bim signal intensity from the 
ethanol-treated acini is shown.
Figure 4
Raf:ER activates AKT in organotypic culture Raf:ER activates AKT in organotypic culture. Raf:ER three-dimensional 
cultures were grown for 10 days, treated with diluent or 100 nM 4-
hydroxytamoxifen (4-HT) and grown for an additional 48 hours. Acini 
were immunostained with both α-phospho-AKTS473 (red, top panels) 
and α-phospho-ERK1/2 (green, bottom panels) and counterstained 
with Hoechst (blue). The same acini are shown in the upper and lower 
panels of each treatment condition to demonstrate the relationship 
between ERK1/2 activation and AKT phosphorylation. There is some 
nonspecific staining of the Matrigel surrounding acini in the phospho-
ERK1/2 images. Bars = 150 μm.Available online http://breast-cancer-research.com/content/11/3/R29
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found that Raf:ER activation increases the fraction of the cells
that immunostain positive for phospho-Ser473 AKT (Figure 4,
upper panels). The stochastic nature of AKT phosphorylation
we observed is consistent with the pattern of AKT phosphor-
ylation in normal MCF-10A acini earlier in their development
[21]. Consistent with increased Raf:ER expression being
observed in the majority of cells in an acinus, the majority of
cells stained positive for phospho-ERK1/2 (Figure 4, lower
panels). Although AKT phosphorylation occurred exclusively in
acini where phosphorylated ERK1/2 was detected (Figure 4),
however, double staining for phospho-ERK and phospho-AKT
showed that activated Akt was only present in a fraction of
cells with activated ERK. The stochastic pattern of AKT serine
473 phosphorylation is therefore unlikely to be due to varia-
tions in Raf:ER expression or ERK1/2 activity, but it does
depend on ERK activation. We did not detect phospho-
Ser473-AKT until 24 hours after Raf:ER activation, whereas
increased expression of c-Fos and phosphorylation of p90
ribosomal S6 kinase (p90RSK), a direct target of ERK1/2,
were first observed 2 hours after 4-HT treatment (data not
shown).
These collective results suggest that ERK1/2 regulation of
AKT is indirect. Whether AKT phosphorylation is observed
only in a small fraction of cells because AKT is phosphorylated
and dephosphorylated in an oscillatory fashion, or whether
there are variations in the strength of autocrine/paracrine stim-
ulation leading to AKT activation, is not known.
Raf:ER-induced disruption of epithelial architecture 
requires phosphoinositide-3 kinase activity
It is likely that the induction of Raf:ER leads to phosphoi-
nositide-3 kinase (PI-3K) activation, since it is known that PI-
3K activity is required for phosphorylation of AKT serine 473.
We therefore next set out to determine the relative importance
of MEK1/2–ERK1/2 and PI-3K signaling in stimulating the
phenotypes observed in Raf:ER-induced acini using pharma-
cological inhibitors. Cells were grown for 10 days or more and
were treated with 100 nM 4-HT for 48 hours with or without
the inhibitor. As expected, inhibition of MEK1/2 with 10 μM
U0126 prevented any gross change in acinar morphology
(Figure 5a). Blockade of PI-3K with 50 μM LY294002 also
prevented Raf:ER-induced morphological changes (Figure 5a,
upper panels). These results suggest that PI-3K activity is
required for the disruption of mammary epithelial architecture
induced by Raf:ER activation.
As discussed above, we have previously developed a method
for imaging cells in Raf:ER-induced acini at single-cell resolu-
tion through imaging a histone–GFP fusion protein, H2B-GFP.
Using this unbiased discovery approach we have found that
Raf:ER activation induces a non-invasive form of motility that
promotes the disruption of epithelial architecture. How cells
become motile in response to either ERK1/2 activation or prior
to invasion is not known. Defining both how ERK1/2 activation
induces movement and also how movement is induced in mul-
ticellular epithelial acini is necessary to understand how cells
become motile and invasive during breast cancer progression.
Raf:ER acini were grown for 10 or days more in organotypic
culture and the acini were stimulated with 100 nM 4-HT in the
presence or absence of the PI-3K inhibitor LY294002. We
found that the treatment of acini with LY294002 was sufficient
to block the induction of noninvasive motility in all of the acini
that were stimulated by Raf:ER activation (Figure 5b and see
Additional files 1 to 3). In contrast, over 50% of the Raf:ER-
induced acini contained five or more motile cells under these
conditions. These results demonstrate that the disruption of
epithelial architecture induced by Raf:ER requires differenti-
ated mammary epithelial cells to integrate signals from both
ERK1/2 and PI-3K. This is the first demonstration that PI-3K
activity is necessary for motility in mammary epithelial acini or
in response to ERK1/2 activation.
PI-3K activity is not necessary for reduced cell–cell 
adhesion or the induction of MLC2 phosphorylation by 
ERK1/2
We next investigated the molecular basis for the requirement
of PI-3K activity in the induction of cell motility. We have
shown previously that Raf:ER activation induces cells to move
independently of each other, and that this independent move-
ment correlates with the loss of E-cadherin at cell–cell con-
tacts [25]. We examined whether PI-3K activity was necessary
for the loss of E-cadherin induced by Raf:ER, and found that
treatment of acini with LY294002 had no effect on the loss of
E-cadherin at cell–cell contacts (Figure 6a, upper panels).
The induction of non-invasive motility in response to Raf:ER
activation requires the phosphorylation of MLC2 in a Rho
kinase-dependent and myosin light-chain kinase-dependent
manner [25]. The pharmacological blockade of PI-3K activity
prevents RhoA and Rho kinase activation in neutrophil-like HL-
60 cells [39], which suggested to us that the inhibition of PI-
3K could be reducing the level of MLC2 phosphorylation and
contraction in the Raf:ER-induced acini. We treated day 10
acini with diluent or LY294002 at the time of Raf:ER activation
and examined the MLC2 phosphorylation at Ser19 using a
phoshospecific antibody. The treatment of acini with
LY294002 did not reduce MLC2 phosphorylation at Ser19 in
response to Raf:ER activation or GFP-Raf:ER activation under
conditions where AKT phosphorylation is reduced (Figure 6a,
lower panels, and 6b). Only of a subset of acini show GFP–
Raf:ER expression because the cell line did not undergo drug
selection to select for GFP–Raf:ER. Also, GFP–Raf:ER
expression is increased after treatment with 4-HT because of
increased protein stability [29]. Our results indicate that PI-3K
is necessary for at least one more additional step for cells to
become motile since PI-3K activity is not required for either the
reduction of E-cadherin expression or for the phosphorylation
of MLC2 on Ser19.Breast Cancer Research    Vol 11 No 3    Pearson and Hunter 
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ERK1/2 activation of AKT correlates with reduced p27 
expression
Real-time imaging showed that cells in Raf:ER-induced acini
did not divide when they were treated with LY294002. Con-
sistent with this observation, the substantial increase in the
number of acini containing two or more cells with phospho-
AKT (Figure 4, upper panels) suggested a role for AKT in cell
proliferation in organotypic culture. The transition from G1 into
the S phase of the cell cycle requires a reduction in the expres-
sion of the Cdk inhibitor protein p27 [40], which in part is reg-
ulated by AKT [41]. Failure to suppress p27 expression
prevents expression of cyclin B1 and activation of Cdk1 [42].
Acini expressing activated Raf:ER had few if any cells express-
ing p27 but contained a number of cells expressing cyclin B1
(Figure 7a, upper panels). Because we can examine biochem-
ical signal transduction pathways at single cell resolution, we
were able to directly compare the activation state of AKT with
the expression of p27. We found an inverse correlation
between AKT activation and p27 expression, as p27 was not
detected in any cells containing detectable levels of phospho-
AKT (Figure 7a, lower panels). This result strongly suggests
that AKT stimulates cell cycle progression by suppressing the
expression of p27 in our model.
PI-3K activity is necessary for Raf:ER-stimulated p27 
degradation and cyclin B induction
To determine whether PI-3K and AKT activity was indeed
required for proliferation, day 10 acini or later acini were
treated with 100 nM 4-HT for 48 hours with or without inhibi-
tor. Inhibiting MEK1/2 or PI-3K was sufficient to prevent AKT
activation, the suppression of p27 expression, and cyclin B1
induction (Figure 7b).
In monolayer culture, autocrine EGFR activation is necessary
to activate AKT [30], so we determined whether autocrine
EGFR activation is necessary for AKT activation in organotypic
culture. EGFR activity was not necessary for activation of AKT
in 4-HT-treated Raf:ER acini, however, and consequently
AG1478 had no effect on the suppression of p27 and cyclin
B1 induction (Figure 7b,c). Furthermore, EGFR inhibition was
Figure 5
Phosphoinositide-3 kinase activity is necessary for the disruption of epithelial architecture Phosphoinositide-3 kinase activity is necessary for the disruption of epithelial architecture. (a) Acini were grown for 10 days and then treated with 
diluent, 100 nM 4-hydroxytamoxifen (4-HT) or 100 nM 4-HT and inhibitor. U0126 (10 μM) and LY294002 (50 μM) were used. Fresh media with dilu-
ent, with 4-HT or with 4-HT and inhibitor was added after 24 hours primary treatment, and acini were cultured for another 24 hours (48 hours total 
treatment time). Bar = 150 μM. DIC, differential interference contrast microscopy; DMSO, dimethylsulfoxide. (b) Day 10 Raf:ER-H2B:GFP acini 
were treated with diluent, 100 nM 4-HT or 100 nM 4-HT and 50 μM LY294002 (phosphoinositide-3 kinase inhibitor) for 24 hours and then imaged 
for 20 hours at 30-minute intervals. The total movement of the cells of a representative acinus from each condition from three independent experi-
ments is shown. The H2B:GFP-labeled nuclei are at white and are located at their respective positions at the end of the 20 hours of imaging. 
Colored scale bar represents increasing time. Results shown are representative of at least 10 acini imaged per condition in three independent exper-
iments.Available online http://breast-cancer-research.com/content/11/3/R29
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also ineffective compared with either MEK1/2 or PI-3K block-
ade at reducing proliferation as judged by Ki-67 expression
(Figure 7d).
Since the concentration of AG1478 used blocked the growth
of co-cultured MCF-10A cells (Figure 2b), the failure of
AG1478 to block AKT phosphorylation, p27 degradation or
Ki-67 expression was probably not due to a failure to inhibit
EGFR.
These results demonstrate that the PI-3K–AKT signaling path-
way is necessary for ERK1/2 signaling to stimulate prolifera-
tion in differentiated mammary epithelial acini.
Discussion
We have demonstrated that the persistent activation of the
Raf–MEK1/2–ERK1/2 mitogen-activated protein kinase mod-
ule promotes the development of pre-invasive mammary
lesions from differentiated epithelium in organotypic culture.
This finding indicates that persistent ERK1/2 activation in lumi-
nal epithelial cells might contribute to the development of
mammary tumors. It is known that ERK1/2 is activated by
oncogenes, such as ErbB2; however, our results demonstrate
that persistent activation of ERK1/2 can induce growth and
survival in the absence of receptor tyrosine kinase mutation or
overexpression. It is possible that unidentified genetic abnor-
malities, or combinations of abnormalities, promote activation
of ERK1/2 in mammary epithelium. This conclusion is sup-
ported by the observation that persistent ERK1/2 activation is
found in a wide range of patient-derived mammary tumor cell
Figure 6
Phosphoinositide-3 kinase activity is not necessary for reduced cell–cell adhesion or MLC2 (Ser-19) phosphorylation Phosphoinositide-3 kinase activity is not necessary for reduced cell–cell adhesion or MLC2 (Ser-19) phosphorylation. (a) Raf:ER acini were treated 
with diluent, with 100 nM 4-hydroxytamoxifen (4-HT) or with 100 nM 4-HT and inhibitor as indicated after at least 10 days of growth in organotypic 
culture. Acini were immunostained with either anti-E-cadherin (red, top panels) or anti-phospho-MLC2 (Ser-19) (red, bottom panels) antibodies and 
counterstained with Hoecsht (blue, nuclei). Results are representative of at least three independent experiments. Bar = 30 μm. DMSO, dimethylsul-
foxide. (b) Green fluorescence protein (GFP)–Raf:ER acini were cultured as described in (a). Acini were immunostained with anti-phospho-MLC2 
(Ser-19) antibody (red, top panels) and counterstained with Hoecsht (blue). The expression of GFP-Raf:ER (green) is shown in the bottom panels. 
Bar = 50 μm.Breast Cancer Research    Vol 11 No 3    Pearson and Hunter 
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lines, many of which do not harbor amplified expression of
ErbB2 [43] and the sequencing of breast cancer tumor
genomes [5]. Furthermore, by uncoupling the activation of the
Raf–MEK1/2–ERK1/2 module from a specific oncogenic
lesion, our results suggest that the inappropriate expression of
growth factor receptor ligands could promote tumorigenesis
through the sustained stimulation of ERK1/2.
The number of ductal carcinoma in situ (DCIS) cases identi-
fied in the United States annually has risen from 4,800 in 1983
to over 50,000 today [4]. After identification, DCIS lesions are
surgically removed with a breast-conserving excision and
patients may undergo either a course of adjuvant therapy tar-
geted to block the action of the hormone estrogen or receive
gamma irradiation to kill the remaining proliferating tumor cells
[4]. The risk of a recurrent growth developing 15 years after
lumpectomy is between 16 and 19%, and thus patients are
required to undergo continual surveillance [44]. One-half of
recurrent growths are invasive breast cancer, which is more
difficult treat and pose a much greater threat of metastasis
[44-46]. It is likely that early-stage epithelial tumors, such as
DCIS, are susceptible to new and more efficacious diagnostic
tests and forms of therapy. Our results demonstrate that
ERK1/2 activation is sufficient to promote proliferation and cell
survival in the lumens of mammary epithelial acini, which are
characteristic behaviors required for recurrent tumor growth
after lumpectomy.
These findings warrant further investigation of the activity level
of the ERK1/2 signaling pathway in patient samples to deter-
mine the frequency of ERK1/2 activation in early-stage breast
cancer and whether there is a correlation between ERK1/2
activation and recurrent growth after lumpectomy. In the event
that a positive connection between ERK1/2 activation and
recurrent growth is revealed, there are a number of inhibitors
of MEK1/2, the direct upstream activators of ERK1/2, that
Figure 7
Cell cycle progression in Raf:ER-stimulated acini requires phosphoinositide-3 kinase activity Cell cycle progression in Raf:ER-stimulated acini requires phosphoinositide-3 kinase activity. (a) (Top panels) Acini were immunostained with α-cyc-
lin B1 (green) or α-p27 (red) and counterstained with Hoechst (blue). (Bottom panels) Acini were immunostained with α-phospho-AKTS473 (green) or 
α-p27 (red) and counterstained with Hoechst (blue). (b) Acini were grown for 10 days and then treated with diluent, with 100 nM 4-hydroxyta-
moxifen (4-HT) or with 100 nM 4-HT and inhibitor. U0126 (10 μM), LY294002 (50 μM) and AG1478 (300 nM) were used. Fresh media with, dilu-
ent, with 4-HT or with 4-HT and inhibitor was added after 24 hours of primary treatment, and acini were cultured for another 24 hours (48 hours total 
treatment time). (Upper panels) α-c-Fos (red) and α-phospho-AKTS473 (green). (Lower panels) α-p27 (red) and α-cyclin B (green). All samples were 
counterstained with Hoechst (blue). Bar = 30 μm. DMSO, dimethylsulfoxide. (c) The number of acini containing at least two phospho-AKTS473-posi-
tive cells was scored. Data are the mean ± standard error of the mean of 100 acini scored in three independent experiments. (d) The percentage of 
acini containing three or more Ki-67 cells was quantified. Data are the mean ± standard error of the mean of 100 acini counted in three independent 
experiments.Available online http://breast-cancer-research.com/content/11/3/R29
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have undergone various stages of in clinical testing and could
be tested as adjuvant therapy in the clinic [47].
Bim and c-Fos of targets of ERK1/2 signaling in 
differentiated mammary epithelial acini
We have identified c-Fos and Bim as downstream effectors of
ERK1/2 that can contribute to the proliferation and survival of
differentiated mammary epithelial cells in the lumens of epithe-
lial acini. These targets of ERK1/2 signaling are worthy of
investigation in patient samples to determine whether ERK1/2
signaling promotes early-stage human breast cancer progres-
sion through similar mechanisms to those observed in organ-
otypic culture.
In addition to promoting c-Fos expression and Bim degrada-
tion, ERK1/2 directly phosphorylates a vast array of proteins
that are also likely to contribute to the observed phenotypes.
For instance, p90 RSK1/2 are activated by direct ERK phos-
phorylation on serine 363, in the linker between the N-terminal
and C-terminal catalytic domains, and threonine 573, in the
activation loop of the C-terminal catalytic domain, resulting in
autophosphorylation at serine 380 and creation of a docking
site for PDK1, which then phosphorylates serine 239 [48,49].
Once activated, p90 RSK1/2 promotes transcription through
direct phosphorylation of transcription factors including the
serum response factor and c-Fos [50-52]. The transcriptional
co-activator CREB binding protein is also a target for p90
RSK [53]. Furthermore, p90 RSK can promote cell survival
through the phosphorylation and inactivation of the Bcl-2-
associated death promoter protein and the activation of the
mammalian target of rapamycin protein by phosphorylating
and inactivating tuberous sclerosis complex 2 [54,55].
This is just one of many examples of the molecular mecha-
nisms by which ERK1/2 can promote pre-invasive tumor
growth. The identification of the ERK1/2 substrates that are
required to promote cell growth and survival will further pro-
vide a molecular framework with which to understand pre-inva-
sive tumor development.
PI-3K activity is necessary for ERK1/2-stimulated 
proliferation
We have shown that the persistent activation of ERK1/2
increases the activity of the parallel PI-3K–AKT signaling mod-
ule, but in a stochastic manner in cells within an acinus. The
activity of the PI-3K, and possibly AKT, is necessary for the
progression of MCF-10A cells through the cell cycle, as has
been previously demonstrated in fibroblasts [42]. The identity
of the signaling circuit connecting ERK1/2 to PI-3K in epithe-
lial organotypic culture is not known. Interestingly, autocrine
activation of EGFR was not necessary for AKT activation in our
organotypic culture model, which is in contrast to results that
were obtained when Raf:ER was induced in MCF-10A cells
grown as two-dimensional monolayers [30]. This discrepancy
could be due to subtle variations between MCF-10A cell lines
or differences in the expression level of the Raf:ER protein.
Alternatively, a distinct mechanism by which ERK1/2 signaling
activates PI-3K could be present in organotypic culture, and
possibly in vivo. For example, although EGFR activation per se
is not necessary for proliferation of Raf:ER-induced acini, we
do not rule out a role for autocrine growth factors in Raf:ER-
stimulated proliferation or PI-3K activation in organotypic cul-
ture. This is because Raf:ER activation promotes the autocrine
production of FGF-2 and VEGF, which act on non-EGFR
receptor tyrosine kinases, and of heparin-binding EGF, which
can elicit heterodimerization of ErbB4 with ErbB2 [30]. Each
of these factors activates receptors or receptor combinations
that are capable of activating PI-3K, and thus one or more of
these autocrine ligands could promote the phosphorylation
and activation of PI-3K and AKT in our model.
PI-3K activity is necessary for ERK-stimulated motility
Our understanding of how cells become motile in response to
ERK1/2 activation is limited. ERK1/2 can phosphorylate
myosin light-chain kinase to promote myosin contraction and
can also phosphorylate calpain to promote the severing of
integrin attachment to substratum in fibroblasts [56,57]. We
have shown that ERK1/2 promotes MLC2 phosphorylation
through myosin light-chain kinase in mammary epithelial acini;
however, a pharmacological inhibitor of calpain has had no
effect on cell motility in our model (GW Pearson, unpublished
observation). The targets of ERK1/2 signaling that regulate
cell motility in general or in mammary epithelial acini are there-
fore a mystery. We have discovered that PI-3K signaling is
upregulated by ERK1/2, and that PI-3K activity is necessary
for cell motility in mammary epithelial acini. Although PI-3K and
the phospholipid products of PI-3K activity can be elevated
through mutation of the catalytic domain of PI-3K or deletion
of the phosphatase and tensin homolog lipid phosphatase or
amplification and activation of transmembrane receptor pro-
teins, the activation of PI-3K in breast cancer does not require
these mutagenic events [58-60]. It is then possible that ERK1/
2 activity could drive cell movement, in part, through the acti-
vation of PI-3K in some breast cancers.
PI-3K activity is necessary for cell motility in mammary 
epithelial acini
How cells become motile in mammary epithelial acini is not
well understood. We have recently determined that cells can
become motile in the absence of invasion [25]. This finding
has potential clinical relevance, because motile cells could be
present in pre-invasive lesions, such as DCIS, and thus por-
tend a greater risk of future invasive growth. Whether there are
indeed motile cells in pre-invasive lesions is not yet known. A
step towards determining how cells become motile during
tumorigenesis is the identification of the intracellular signaling
pathways that are necessary or sufficient to induce cell move-
ment in these multicellular structures. We have already found
that ERK1/2 activation is sufficient to induce movement and
that this ERK1/2-driven motility requires MLC2 phosphoryla-Breast Cancer Research    Vol 11 No 3    Pearson and Hunter 
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tion and a reduction in E-cadherin expression [25]. We have
now determined that PI-3K activity is necessary for the induc-
tion of motility induced by ERK1/2 signaling in mammary epi-
thelial acini.
The requirement of PI-3K activity for Raf:ER-stimulated cell
motility is independent of MLC2 phosphorylation or E-cad-
herin expression, which suggests that PI-3K regulates at least
one additional process that is necessary for cells to become
motile in mammary epithelial acini. PI-3K signaling has been
extensively studied in the regulation of chemotaxis in the slime
mold Dictyostelium and neutrophils [61]. In these model sys-
tems, PI-3K contributes the production of phosphatidylinositol
(3,4,5)-triphosphate at the leasing edge of the cell, which is
necessary for the polarization of the cell and the directional
migration towards a chemoattractant [61]. PI-3K activity is
necessary for the chemotaxis of additional cell types, including
some patient-derived breast cancer cell lines, possibly through
an analogous mechanism [62]. Whether cells in epithelial acini
are moving by chemotaxis is not known. In fact, cells move in
different directions within an acinus – which suggests that
chemotaxis, and by extension a requirement for sustained
polarization of cells, is not necessary for the movement
observed. Considering this possibility, PI-3K activity probably
regulates motility in mammary epithelial acini through a mech-
anism distinct from the polarization necessary for chemotaxis
observed in other model systems. In the future, determining
how PI-3K regulates movement in mammary epithelial acini will
serve to further explain how cells become motile during breast
cancer progression.
Conclusions
Our results demonstrate that the activation of the Raf–MEK1/
2–ERK1/2 mitogen-activated protein kinase module is suffi-
cient to induce cell proliferation, survival and motility in cul-
tured mammary epithelial acini. In addition, PI-3K activity was
required for proliferation and survival induced by ERK1/2 acti-
vation. Each of these cell behaviors could contribute to recur-
rent and invasive breast cancer growth after lumpectomy,
which suggests that the activity state of the two signaling path-
ways should be investigated in DCIS patients.
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